5 results about "Lymphatic oedema" patented technology

This invention relates to a method for calculating and correcting the volume of a limb with lymphedema. The method involves acquiring the outer contour data of the limb with lymphedema under a first and second standard measurement position, and dividing the limb into segments along its length with equal intervals to obtain two sets of corresponding volume segments. The volume of each corresponding segment is calculated, and the volume difference for the same segment number is determined. The volume segment whose absolute value of the volume difference is greater than a preset threshold is identified as the target volume segment. Based on the correspondence of the local volume distribution of the target volume segment in the two sets of volume segments, the volume difference is determined to be either a solid increment or a positional drift increment. Using the volume of each volume segment under the first standard measurement position as a benchmark, the solid increment is retained in the target volume segment, and the positional drift increment is corrected. The volumes of each volume segment after correction are summed to obtain the corrected volume of the limb with lymphedema.

This invention relates to the field of biomedical technology and provides the application of taquimod in the preparation of drugs for regulating lymphatic inflammatory responses. Through bioinformatics analysis and cell experiments, this invention demonstrates that taquimod can specifically inhibit the abnormally activated S100A9 / RAGE signaling pathway in lymphatic inflammation, significantly reduce the expression of inflammatory factors, and effectively restore the proliferation, migration, and tube formation function of lymphatic endothelial cells. This provides a novel drug treatment approach based on molecular mechanisms for treating diseases related to lymphatic inflammatory responses such as lymphedema. Furthermore, taquimod, as an oral formulation with proven safety in clinical trials, exhibits good patient compliance and is suitable for long-term use. Compared to existing symptomatic treatments, it holds promise for fundamentally interrupting the vicious cycle of inflammation that drives disease progression, and thus has significant clinical application potential.

1. The name of the design product: portable lymphedema treatment instrument. 2. The use of the design product: for lymphedema treatment. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

This application discloses a BCRL risk prediction method and management system based on a patient 360-degree view, belonging to the field of medical information technology. This application obtains static medical data of patients from a locally pre-set patient 360-degree view system and dynamic postoperative data of patients before discharge; based on the static medical data and dynamic postoperative data, a pre-set risk scoring model is used to determine the real-time risk value of lymphedema in patients; and based on the real-time risk value, static medical data, and dynamic postoperative data, the postoperative recovery level of target patients is risk-stratified; based on the risk stratification results, an adaptive follow-up plan is generated, wherein the adaptive follow-up plan includes at least differentiated follow-up frequencies and follow-up content for different patients and / or the same patient; the adaptive follow-up plan is sent to relevant medical personnel for execution, and for regular monitoring of the postoperative lymphedema risk of each patient.

This invention belongs to the field of pharmaceutical technology and relates to the research and application of drugs for the treatment of lymphedema, specifically the application of systemic artemisinin in the treatment of secondary lymphedema. Specifically, this invention provides the use of artemisinin or its derivatives in the preparation of drugs or formulations for the prevention and / or treatment of lymphedema, wherein the drugs or formulations are used to: relieve lymphedema, relieve fat deposition caused by lymphedema, and / or promote lymphatic vessel regeneration.